Glucose-Sensitive Insulin Conjugate for Dynamic Release Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current controlled-release drug delivery systems are inadequate for managing insulin levels in diabetes, as they fail to provide proportional insulin release in response to varying blood glucose concentrations, leading to ineffective prevention of pathological sequelae.
Innovation Solution
A conjugate is developed comprising an insulin molecule with an affinity ligand covalently bound to the A-chain and a monovalent glucose binding agent covalently bound to the B-chain, where the affinity ligand competes with glucose for binding with the glucose binding agent, switching the insulin from an inactive to an active form based on glucose levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If controlled-release drug delivery systems are used to slow or delay insulin release, then fewer peaks and troughs in serum profile are achieved, but the system cannot provide proportional insulin release in response to varying blood glucose concentrations
Solution Approach 1:
The patent applies dynamics by creating a reversible non-covalent interaction between the affinity ligand and monovalent glucose binding agent that responds dynamically to glucose concentration changes. The interaction strength varies with glucose levels, enabling the system to transition between bound and unbound states, thereby providing proportional insulin release in response to varying blood glucose concentrations while maintaining stable serum profile.
Solution Approach 2:
The patent utilizes parameter changes by exploiting the concentration-dependent binding affinity between the affinity ligand and monovalent glucose binding agent. As glucose concentration changes, the binding equilibrium shifts, altering the fraction of active insulin molecules. This parameter-based control enables the system to adapt insulin release to glucose levels while maintaining overall profile stability.
2Ease of manufacture
If simple replacement of insulin hormone is used, then the treatment is straightforward, but it cannot prevent pathological sequelae associated with diabetes
Solution Approach 1:
The patent introduces an intermediary mechanism—the reversible non-covalent interaction between the affinity ligand and monovalent glucose binding agent—that mediates between glucose sensing and insulin release. This intermediary system translates glucose concentration information into proportional insulin activation, enabling effective prevention of diabetic complications while maintaining treatment feasibility through a modular conjugate design.
3Adaptability or versatility
If conjugate with affinity ligand and monovalent glucose binding agent is used, then glucose-sensitive insulin activation is achieved, but the molecular structure becomes more complex
Solution Approach 1:
The patent applies segmentation by dividing the insulin molecule into functional segments: the A-chain with covalently bound affinity ligand, the B-chain with covalently bound monovalent glucose binding agent, and the reversible non-covalent interaction interface. This segmentation allows each component to perform its specific function while maintaining overall system functionality with manageable complexity.
Solution Approach 2:
The patent creates a composite molecular structure by covalently combining the affinity ligand to the A-chain and the monovalent glucose binding agent to the B-chain of the insulin molecule. This composite conjugate integrates multiple functional elements (insulin activity, glucose sensing, affinity competition) into a single molecular entity, achieving glucose-sensitive activation while managing structural complexity through precise molecular design.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach allows for a glucose-sensitive switch in insulin activity, enabling tailored insulin release in response to local glucose concentrations, potentially improving glycemic control and preventing diabetes-related complications.
Implementation Method 1
the affinity ligand competes with glucose for non-covalent binding with the monovalent glucose binding agent
Implementation Method 2
When free glucose is added, it competes with the affinity ligand for binding with the monovalent glucose binding agent to produce an open active form of the insulin molecule
Data Source
AI summary
In one aspect, the disclosure provides a conjugate comprising an insulin molecule having an A-chain and a B-chain; an affinity ligand covalently bound to the A-chain; and a monovalent glucose binding agent covalently bound to the B-chain, wherein the affinity ligand competes with glucose for non-covalent binding with the monovalent glucose binding agent. In the absence of glucose, the monovalent glucose binding agent binds the affinity ligand to produce a “closed” inactive form of the insulin molecule. When free glucose is added, it competes with the affinity ligand for binding with the monovalent glucose binding agent to produce an “open” active form of the insulin molecule. The monovalent glucose binding agent and affinity ligand are covalently bound to the insulin molecule. The disclosure also provides methods of using these conjugates and methods of making these conjugates. In another aspect, the disclosure provides exemplary conjugates. The disclosure also provides alternative conjugates that are not necessarily activated by glucose.